drugset / Trial / NCT01129271

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

NCT01129271 ↗

Phase 1 Completed 72 enrolled Sanofi Bristol-Myers Squibb · collab
RandomizedCrossoverDouble-blindBasic science

Summary

Primary objective: * Investigate the potential food effect on Adenosine diphosphate(ADP)-induced platelet aggregation after 5-day repeated doses of clopidogrel (300 mg loading dose followed by 4 days 75 mg/day) in healthy subjects Secondary objectives are to investigate the potential food effect on: * ADP-induced platelet aggregation after 300 mg loading dose of clopidogrel * Pharmacokinetic profiles of clopidogrel and its active metabolite after 5-day repeated doses of clopidogrel

Timeline

Start
2009-04
Primary completion
2009-06
Completion
2009-06

Outcome

Met primary endpoint

paper with the 90% CI (0.9%-8.5%) contained within the prespecified equipotency range of ±15%. PMID 22128201 ↗

paper These findings confirm that clopidogrel can be taken with or without food. PMID 22128201 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg Oral

Indications

No indication recorded.